These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 14559126)

  • 21. Combination of low molecular weight heparins with antiplatelet agents in non-ST elevation acute coronary syndromes: an update.
    Cohen M
    Drugs; 2002; 62(12):1755-70. PubMed ID: 12149045
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor combined with low molecular weight heparin in patients with acute coronary syndrome.
    Kim JH; Jeong MH; Rhew JY; Lim JH; Yun KH; Kim KH; Kang DK; Hong SN; Lim SY; Lee SH; Lee YS; Hong YJ; Park HW; Kim W; Ahn YK; Moon Y; Cho JG; Park JC; Kang JC
    Circ J; 2005 Feb; 69(2):159-64. PubMed ID: 15671606
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis.
    Weintraub WS; Culler S; Boccuzzi SJ; Cook JR; Kosinski AS; Cohen DJ; Burnette J
    J Am Coll Cardiol; 1999 Oct; 34(4):1061-6. PubMed ID: 10520791
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Invasive versus conservative strategies in unstable angina and non-Q-wave myocardial infarction following treatment with tirofiban: rationale and study design of the international TACTICS-TIMI 18 Trial. Treat Angina with Aggrastat and determine Cost of Therapy with an Invasive or Conservative Strategy. Thrombolysis In Myocardial Infarction.
    Cannon CP; Weintraub WS; Demopoulos LA; Robertson DH; Gormley GJ; Braunwald E
    Am J Cardiol; 1998 Sep; 82(6):731-6. PubMed ID: 9761082
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A comparison of two invasive strategies in patients with non-ST elevation acute coronary syndromes: results of the Early or Late Intervention in unStable Angina (ELISA) pilot study. 2b/3a upstream therapy and acute coronary syndromes.
    van 't Hof AW; de Vries ST; Dambrink JH; Miedema K; Suryapranata H; Hoorntje JC; Gosselink AT; Zijlstra F; de Boer MJ
    Eur Heart J; 2003 Aug; 24(15):1401-5. PubMed ID: 12909068
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Platelet glycoprotein IIb/IIIa inhibitors in coronary artery disease].
    Auer J; Berent R; Lassnig E; Weber T; Maurer E; Eber B
    Herz; 2003 Aug; 28(5):393-403. PubMed ID: 12928738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of abciximab with "high-dose" tirofiban in patients undergoing percutaneous coronary intervention.
    Gunasekara AP; Walters DL; Aroney CN
    Int J Cardiol; 2006 Apr; 109(1):16-20. PubMed ID: 16014315
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.
    Boersma E; Akkerhuis KM; Théroux P; Califf RM; Topol EJ; Simoons ML
    Circulation; 1999 Nov; 100(20):2045-8. PubMed ID: 10562258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes.
    Cohen M; Théroux P; Weber S; Laramée P; Huynh T; Borzak S; Diodati JG; Squire IB; Deckelbaum LI; Thornton AR; Harris KE; Sax FL; Lo MW; White HD
    Int J Cardiol; 1999 Dec; 71(3):273-81. PubMed ID: 10636535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of tirofiban plus heparin versus heparin alone on troponin I levels in patients with acute coronary syndromes.
    Januzzi JL; Hahn SS; Chae CU; Giugliano R; Lewandrowski K; Theroux P; Jang IK
    Am J Cardiol; 2000 Oct; 86(7):713-7. PubMed ID: 11018188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease.
    Lincoff AM; Califf RM; Topol EJ
    J Am Coll Cardiol; 2000 Apr; 35(5):1103-15. PubMed ID: 10758948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Initial experience with the low-molecular-weight heparin, enoxaparin, in combination with the platelet glycoprotein IIb/IIIa blocker, tirofiban, in patients with non-ST segment elevation acute coronary syndromes.
    Cohen M
    J Invasive Cardiol; 2000 Dec; 12 Suppl E():E5-9;discussion E25-8. PubMed ID: 11156722
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effective treatment of acute coronary syndromes-IIB or not IIB?
    Klein WW
    Eur Heart J; 1999 Sep; 20(17):1217-9. PubMed ID: 10454971
    [No Abstract]   [Full Text] [Related]  

  • 34. Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?
    Schriger DL; Herbert ME
    Ann Emerg Med; 2001 Sep; 38(3):249-55. PubMed ID: 11524643
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic issues in glycoprotein IIb/IIIa receptor therapy.
    Hillegass WB; Newman AR; Raco DL
    Am Heart J; 1999 Jul; 138(1 Pt 2):S24-32. PubMed ID: 10385788
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of enoxaparin and nadroparin on major cardiac events in high-risk unstable angina treated with a glycoprotein IIb/IIIa inhibitor.
    Okmen E; Ozen E; Uyarel H; Sanli A; Tartan Z; Cam N
    Jpn Heart J; 2003 Nov; 44(6):899-906. PubMed ID: 14711185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Benefit of an early invasive management strategy in women with acute coronary syndromes.
    Glaser R; Herrmann HC; Murphy SA; Demopoulos LA; DiBattiste PM; Cannon CP; Braunwald E
    JAMA; 2002 Dec; 288(24):3124-9. PubMed ID: 12495392
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors.
    Adgey AA
    Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between age, outcome of acute coronary syndromes, and tirofiban therapy.
    Januzzi JL; Sabatine MS; Wan Y; Servoss SJ; DiBattiste PM; Jang Ik; Theroux P
    Am J Cardiol; 2003 Feb; 91(4):457-61. PubMed ID: 12586266
    [No Abstract]   [Full Text] [Related]  

  • 40. Net clinical benefit of prehospital glycoprotein IIb/IIIa inhibitors in patients with ST-elevation myocardial infarction and high risk of bleeding: effect of tirofiban in patients at high risk of bleeding using CRUSADE bleeding score.
    Hermanides RS; Ottervanger JP; ten Berg JM; Gosselink AT; van Houwelingen G; Dambrink JH; Stella PR; Hamm C; van 't Hof AW;
    J Invasive Cardiol; 2012 Mar; 24(3):84-9. PubMed ID: 22388296
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.